Welcome!

News Feed Item

Targeted Cancer Drugs The Launch Landscape to 2018

NEW YORK, Dec. 12, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Targeted Cancer Drugs The Launch Landscape to 2018
http://www.reportlinker.com/p0777914/Targeted-Cancer-Drugs-The-Launch-Landscape-to-2018 .html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication



As the cancer therapy market evolves, interest is growing in novel approaches which may supersede the current portfolio. In the short term, the market will be dominated by established therapeutic approaches, but the question is – "What next?"
A sign of things to come?


The end of 2011 saw the US approval of two new molecularly-targeted cancer drugs, alongside companion diagnostic tests that identify the patients most likely to benefit from treatment. Pfizer's Xalkori (crizotinib) and Roche's Zelboraf (vemurafenib) were both approved following a priority review, highlighting the importance that the FDA has placed on hastening the passage of these therapies to market. These approvals reflect the trend of treating cancers based on their molecular and genetic characteristics, rather than their location within the body.



Such developments have long been heralded as marking the future of cancer therapies and the benefits to patients, clinicians and health payers is clear – but are these approvals the benchmark for future developments?



With sales of many blockbuster drugs being cannibalised by generic competitors, pharmaceutical and biotechnology companies are populating their pipelines with candidates directed at novel targets, enhancing development and commercialisation potential. The opportunities for small and medium-sized companies is increasing as the dynamic of the market changes.




This new report provides a complete assessment of the targeted cancer therapy landscape
Packed with statistics, competitive rankings, timelines and sector share comparisons, this report examines the current market for targeted cancer drugs, with an overview of both products and players. Looking ahead, the report identifies 79 new candidates that are currently under a minimum of Phase II development for solid tumours and provides a timeline detailing estimated launch dates to 2018. There is a review of the molecular targets on which industry attention is focused, and the companies involved in the development and commercialisation of the products directed against these targets. Finally, each product is considered individually in terms of its mode of action, current developmental status, clinical data, risks associated with development, developer and potential competition within the marketplace.




The global cancer market is changing fundamentally as broad spectrum drugs are superseded by advanced targeted therapies
Current therapeutic approaches for targeted agents will dominate...
With the success of products directed against established targets, such as ErbB (HER) and VEGF, the search continues for new and improved agents within these groups. For example, Roche is capitalising on the success of its HER2 inhibitor, Herceptin (trastuzumab), with the development of an antibody-drug conjugate, trastuzumab emtansine, which consists of the monoclonal antibody, trastuzumab, linked to the antimicrotubule agent, DM1. Pfizer has developed a multi-kinase inhibitor, dacomitinib, that targets HER1, 2 and 4, and has shown superiority to Roche's Tarceva (erlotinib) in extending progression-free survival in advanced non-small cell lung cancer patients. In addition, a variety of smallmolecule kinase inhibitors that target multiple components of the VEGF pathway and/or other angiogenic pathways are progressing through clinical trials.



...but will candidates directed at novel targets gain ground?
By 2018, Espicom expects that these new developmental candidates will account for 50% of targeted agents on the market by number. Among the pathways - and the products being developed - examined in the report are:



The Met pathway plays an important role in the development of cancer, so interfering with Met signalling would seem to be a promising therapeutic approach and a number of targeted agents are under development.
There is significant research interest in the PI3k/Akt signalling pathway which has shown an impressive improvement in overall survival.
A phosphatidylserine-targeting monoclonal antibody has the potential to be effective against a wide range of solid tumours.
Heat shock proteins are over-expressed in a wide range of human cancers and have been considered a promising target for cancer therapy, although the early Hsp inhibitors were dogged by drug-related toxicities. Those now progressing through clinical trials appear to show greater efficacy and less off-target activity.
How will the competitive landscape be affected?



A number of the larger players will continue to dominate the marketplace into 2018 with Roche, Takeda, Eli Lilly and BMS all estimated to have achieved five or more launches. However, significant opportunities exist for many smaller innovative pharma companies and biotechs, which by their very nature are proficient and well-suited to product development in niche markets.



Questions answered by the report

How many products are profiled treating lung, breast and colorectal cancer?
Which developmental pathways are much fancied to provide significant clinical advances and which companies are involved?
BMS, Eli Lilly, Roche, and Takeda all have five or more products in latestage expected to launch – what are they, what do they target and when are they expected?
What are the prospects for Teva Pharmaceutical Industries' oncology portfolio?
Emerging opportunities: with whom are the smaller companies working and how many have yet to secure development/marketing collaborations?
About the Author: This report has been written by Sue Viney, a senior writer on Espicom's oncology analysis team. Sue has been evaluating companies, products and drugs in research for 12 years. She is editor of Cancer Drug Futures and, in addition, has also produced management reports on the lung, colorectal, prostate and renal cancer areas, as well as studies on rheumatoid arthritis and CNS drug development.


To order this report:
Drug_and_Medication Industry:
Targeted Cancer Drugs The Launch Landscape to 2018

__________________________
Contact Nicolas: [email protected]
US: (805)-652-2626
Intl: +1 805-652-2626

 

SOURCE Reportlinker

More Stories By PR Newswire

Copyright © 2007 PR Newswire. All rights reserved. Republication or redistribution of PRNewswire content is expressly prohibited without the prior written consent of PRNewswire. PRNewswire shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Latest Stories
SYS-CON Events announced today that Venafi, the Immune System for the Internet™ and the leading provider of Next Generation Trust Protection, will exhibit at @DevOpsSummit at 19th International Cloud Expo, which will take place on November 1–3, 2016, at the Santa Clara Convention Center in Santa Clara, CA. Venafi is the Immune System for the Internet™ that protects the foundation of all cybersecurity – cryptographic keys and digital certificates – so they can’t be misused by bad guys in attacks...
The cloud market growth today is largely in public clouds. While there is a lot of spend in IT departments in virtualization, these aren’t yet translating into a true “cloud” experience within the enterprise. What is stopping the growth of the “private cloud” market? In his general session at 18th Cloud Expo, Nara Rajagopalan, CEO of Accelerite, explored the challenges in deploying, managing, and getting adoption for a private cloud within an enterprise. What are the key differences between wh...
For basic one-to-one voice or video calling solutions, WebRTC has proven to be a very powerful technology. Although WebRTC’s core functionality is to provide secure, real-time p2p media streaming, leveraging native platform features and server-side components brings up new communication capabilities for web and native mobile applications, allowing for advanced multi-user use cases such as video broadcasting, conferencing, and media recording.
In his session at Cloud Expo, Robert Cohen, an economist and senior fellow at the Economic Strategy Institute, will provide economic scenarios that describe how the rapid adoption of software-defined everything including cloud services, SDDC and open networking will change GDP, industry growth, productivity and jobs. This session will also include a drill down for several industries such as finance, social media, cloud service providers and pharmaceuticals.
Security, data privacy, reliability, and regulatory compliance are critical factors when evaluating whether to move business applications from in-house, client-hosted environments to a cloud platform. Quality assurance plays a vital role in ensuring that the appropriate level of risk assessment, verification, and validation takes place to ensure business continuity during the migration to a new cloud platform.
SYS-CON Events announced today the Kubernetes and Google Container Engine Workshop, being held November 3, 2016, in conjunction with @DevOpsSummit at 19th Cloud Expo at the Santa Clara Convention Center in Santa Clara, CA. This workshop led by Sebastian Scheele introduces participants to Kubernetes and Google Container Engine (GKE). Through a combination of instructor-led presentations, demonstrations, and hands-on labs, students learn the key concepts and practices for deploying and maintainin...
Aspose.Total for .NET is the most complete package of all file format APIs for .NET as offered by Aspose. It empowers developers to create, edit, render, print and convert between a wide range of popular document formats within any .NET, C#, ASP.NET and VB.NET applications. Aspose compiles all .NET APIs on a daily basis to ensure that it contains the most up to date versions of each of Aspose .NET APIs. If a new .NET API or a new version of existing APIs is released during the subscription peri...
StackIQ has announced the release of Stacki 3.2. Stacki is an easy-to-use Linux server provisioning tool. Stacki 3.2 delivers new capabilities that simplify the automation and integration of site-specific requirements. StackIQ is the commercial entity behind this open source bare metal provisioning tool. Since the release of Stacki in June of 2015, the Stacki core team has been focused on making the Community Edition meet the needs of members of the community, adding features and value, while ...
There will be new vendors providing applications, middleware, and connected devices to support the thriving IoT ecosystem. This essentially means that electronic device manufacturers will also be in the software business. Many will be new to building embedded software or robust software. This creates an increased importance on software quality, particularly within the Industrial Internet of Things where business-critical applications are becoming dependent on products controlled by software. Qua...
In addition to all the benefits, IoT is also bringing new kind of customer experience challenges - cars that unlock themselves, thermostats turning houses into saunas and baby video monitors broadcasting over the internet. This list can only increase because while IoT services should be intuitive and simple to use, the delivery ecosystem is a myriad of potential problems as IoT explodes complexity. So finding a performance issue is like finding the proverbial needle in the haystack.
"We host and fully manage cloud data services, whether we store, the data, move the data, or run analytics on the data," stated Kamal Shannak, Senior Development Manager, Cloud Data Services, IBM, in this SYS-CON.tv interview at 18th Cloud Expo, held June 7-9, 2016, at the Javits Center in New York City, NY.
Machine Learning helps make complex systems more efficient. By applying advanced Machine Learning techniques such as Cognitive Fingerprinting, wind project operators can utilize these tools to learn from collected data, detect regular patterns, and optimize their own operations. In his session at 18th Cloud Expo, Stuart Gillen, Director of Business Development at SparkCognition, discussed how research has demonstrated the value of Machine Learning in delivering next generation analytics to imp...
DevOps at Cloud Expo – being held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA – announces that its Call for Papers is open. Born out of proven success in agile development, cloud computing, and process automation, DevOps is a macro trend you cannot afford to miss. From showcase success stories from early adopters and web-scale businesses, DevOps is expanding to organizations of all sizes, including the world's largest enterprises – and delivering real results. Am...
With the proliferation of both SQL and NoSQL databases, organizations can now target specific fit-for-purpose database tools for their different application needs regarding scalability, ease of use, ACID support, etc. Platform as a Service offerings make this even easier now, enabling developers to roll out their own database infrastructure in minutes with minimal management overhead. However, this same amount of flexibility also comes with the challenges of picking the right tool, on the right ...
The 19th International Cloud Expo has announced that its Call for Papers is open. Cloud Expo, to be held November 1-3, 2016, at the Santa Clara Convention Center in Santa Clara, CA, brings together Cloud Computing, Big Data, Internet of Things, DevOps, Digital Transformation, Microservices and WebRTC to one location. With cloud computing driving a higher percentage of enterprise IT budgets every year, it becomes increasingly important to plant your flag in this fast-expanding business opportuni...